ChemicalBook
Chinese english Germany Japanese Korea

Bosutinib Produkt Beschreibung

Bosutinib Struktur
380843-75-4
CAS-Nr.
380843-75-4
Englisch Name:
Bosutinib
Synonyma:
CS-311;SKI-606;Bsutinib;Bosulif);BOSUTINIB;WAY-173606;Bosutinib control;Bosutinib(TINIBS );Bosulif(bosutinib);SKI 606 - Bosutinib
CBNumber:
CB6504575
Summenformel:
C26H29Cl2N5O3
Molgewicht:
530.45
MOL-Datei:
380843-75-4.mol

Bosutinib Eigenschaften

Schmelzpunkt:
116-120 ºC
Siedepunkt:
649.7±55.0 °C(Predicted)
Dichte
1.36
storage temp. 
room temp
Löslichkeit
DMSO: ≥15mg/mL
pka
7.63±0.10(Predicted)
Aggregatzustand
powder
Farbe
off-white to light brown
InChIKey
PICKMQXYAMDEPF-UHFFFAOYSA-N
CAS Datenbank
380843-75-4(CAS DataBase Reference)
Sicherheit
  • Risiko- und Sicherheitserklärung
  • Gefahreninformationscode (GHS)
Kennzeichnung gefährlicher Xi
R-Sätze: 36
S-Sätze: 26
WGK Germany  3
HS Code  29335990
Bildanzeige (GHS)
Alarmwort Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H319 Verursacht schwere Augenreizung. Schwere Augenreizung Kategorie 2 Warnung P264, P280, P305+P351+P338,P337+P313P
H413 Kann für Wasserorganismen schädlich sein, mit langfristiger Wirkung. Langfristig (chronisch) gewässergefährdend Kategorie 4
Sicherheit
P305+P351+P338 BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen.

Bosutinib Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

In September 2012, the US FDA approved bosutinib (also referred to as SKI-607) for the treatment of relapsed or refractory chronicmyeloid leukemia (CML) for patients with resistance or intolerance to prior therapy. The National Cancer Institute estimates that in 2012, 5430 men and women were diagnosed with CML and 610 died of CML. First and second-line therapies for the treatment of CML include imatinib, dasatinib, and nilotinib. Bosutinib, which was initially identified as a Src inhibitor, was later found to be a dual inhibitor of Bcr–Abl (IC50=1.4 nM) and Src family kinases (IC50=3.5 nM). Bosutinib inhibits 16 of 18 imatinib-resistant forms of Bcr–Abl expressed in murine myeloid cell lines. In preclinical in vivo studies, bosutinib at 15 mg/kg administered orally for 5 days caused regression of K562 CML tumors in nude mice and in BaF3 tumors expressing wild type or different imatinib-resistant Bcr–Abl mutants at varying doses. A manufacturing process for the synthesis of bosutinib monohydrate has been reported that employs a key three-component cyclization reaction involving an aniline, a cyanoacetamide intermediate, and triethyl orthoformate followed by cyclization using phosphorous oxytrichloride and an optimized hydration procedure.

Chemische Eigenschaften

Pale Yellow Solid

Originator

Wyeth (United States)

Verwenden

A novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.

Verwenden

peripheral vasolidator increases cerebral blood flow, potential therapeutic for Altzheimer’s disease, cognitive impairment and dementia

Verwenden

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM, respectively.

Definition

ChEBI: An aminoquinoline that is 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline bearing additional cyano and methoxy substituents at positions 3 and 6 respectively.

Trademarks

Bosulif

Allgemeine Beschreibung

Bosutinib is a safe oral medicine with good bioavailability. It is effective for treating chronic myeloid leukemia (CML). It is also a potent ATP-competitive inhibitor for Src tyrosine kinase. Bosutinib inhibits epidermal growth factor receptor (EGFR). It suppresses solid tumors associated with breast, pancreas and prostate.

Biochem/physiol Actions

Bosutinib (SKI-606) is an orally active; dual Src/Abl tyrosine kinase inhibitor with potent antiproliferative activity. It does not appear to inhibit c-Kit and PDGRF, which are thought to be the cause of numerous side effects in anticancer treatment with some other tyrosine kinase inhibitors.

Bosutinib Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Bosutinib Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 297)Lieferanten
Firmenname Telefon Fax E-Mail Land Produktkatalog Edge Rate
AFINE CHEMICALS LIMITED
008657185134551
008657185134895 info@afinechem.com CHINA 15559 58
Capot Chemical Co.,Ltd.
+86(0)13336195806 +86-571-85586718
+86-571-85864795 sales@capotchem.com China 20012 60
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com China 22607 55
Guangzhou PI PI Biotech Inc
+8618371201331
020-81716319 sales@pipitech.com;87478684@qq.com China 3284 55
ATK CHEMICAL COMPANY LIMITED
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 ivan@atkchemical.com CHINA 26781 60
career henan chemical co
+86-0371-55982848
sales@coreychem.com China 29953 58
Zhejiang ZETian Fine Chemicals Co. LTD
18957127338
stella@zetchem.com China 2008 58
Biochempartner
0086-13720134139
candy@biochempartner.com CHINA 968 58
GIHI CHEMICALS CO.,LIMITED
08657186217390
sales@gihichemicals.com CHINA 310 58
Hubei Jusheng Technology Co.,Ltd.
86-18871470254
027-59599243 linda@hubeijusheng.com CHINA 28229 58

380843-75-4()Verwandte Suche:


  • 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile
  • Bosutinib ( SKI-606 )
  • Bsutinib
  • SKI 606 - Bosutinib
  • CS-311
  • Bosutinib for research
  • 3-Quinolinecarbonitrile, 4-[(2,4-dichloro-5-Methoxyphenyl)aMino]-6-Methoxy-7-[3-(4-Methyl-1-piperazinyl)propoxy]-
  • Bosutinib(TINIBS )
  • WAY-173606
  • Bosulif(bosutinib)
  • 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile Bosutinib (SKI-606)
  • BOSUTINIB (SKI-606);SKI-606
  • SKI-606
  • BOSUTINIB
  • Bosutinib control
  • Bosutinib USP/EP/BP
  • Bosutinib formate salt
  • Bosulif)
  • 380843-75-4
  • C26H29Cl2N5O3
  • Aromatics
  • Heterocycles
  • Inhibitors
  • Aromatics Compounds
  • API
  • Intermediates & Fine Chemicals
  • Pfizer compounds
  • Pharmaceuticals
Copyright 2019 © ChemicalBook. All rights reserved